Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin
Source abstract
Abstract
Vemurafenib is a chemotherapeutic drug recently approved by the FDA to treat melanoma. Because the drug is usually delivered orally, the route of administration readily causes damage to major organs with limited antitumor efficacy and bioavailability. In this study, we developed a peptide-modified vemurafenib-loaded liposome for the targeted inhibition of subcutaneous melanoma via the skin. First, the peptide-modified vemurafenib-loaded liposomes (Vem-TD-Lip) were prepared and characterized with respect to the size, shape and charge; the loading efficiency of vemurafenib; and the stability. Then, the intracellular uptake of these liposomes, their limited cytotoxicity, the selective inhibition of melanoma cells harboring BRAF mutations, and the liposome permeation ability were confirmed through in vitro experiments. Finally, the safety and antitumor activity of Vem-TD-Lip were evaluated in vivo. The results showed that transdermal delivery of Vem-TD-Lip effectively targeted and inhibited subcutaneous melanoma in male mice, the administration of Vem-TD-Lip through skin was better than that through oral administration and intravenous injection in terms of reducing damage to major organs and enhancing antitumor efficacy, and the peptide TD significantly enhanced the delivery of Vem-TD-Lip across the skin. This work provides a new strategy for delivering vemurafenib to target and inhibit subcutaneous melanoma.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Immunotherapy and Immune Responses · Advancements in Transdermal Drug Delivery · Cell Adhesion Molecules Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Recent advances in targeted nanoparticles drug delivery to melanoma10.1016/j.nano.2014.11.006 ↗
2. Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition10.1038/onc.2017.391 ↗
3. Vemurafenib for the treatment of BRAF mutant metastatic melanoma10.2217/fon.14.252 ↗
4. Nanographene oxide-hyaluronic acid conjugate for photothermal ablation therapy of skin cancer10.1021/nn405383a ↗
5. Imiquimod enhances the effect of cryotherapy in the management of cutaneous melanoma metastases: a retrospective study of 20 patients
6. Therapy for metastatic melanoma: the past, present, and future10.1186/1741-7015-10-23 ↗
7. Research progress in advanced melanoma10.1016/j.canlet.2017.03.037 ↗
8. Atkins · J. Clin. Oncol. · 2008 · 26 · 574810.1200/JCO.2008.17.5448 ↗
9. Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy10.1016/j.biotechadv.2016.01.004 ↗
10. Mutation-driven drug development in melanoma10.1097/CCO.0b013e32833888ee ↗
11. Vemurafenib: the first drug approved for BRAF-mutant cancer10.1038/nrd3847 ↗
12. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
13. Improved survival with vemurafenib in melanoma with BRAF V600E mutation10.1056/NEJMoa1103782 ↗
14. Survival in BRAF V600-Mutant advanced melanoma treated with vemurafenib10.1056/NEJMoa1112302 ↗
15. Dias · Eur J Cancer · 2013 · 49 · 165410.1016/j.ejca.2013.01.015 ↗
16. Vemurafenib induces senescence features in melanoma cells10.1038/jid.2013.6 ↗
17. Design and development of fluorescent vemurafenib analogs for in vivo imaging10.7150/thno.18238 ↗
18. Vemurafenib-induced granulomatous hepatitis10.1002/hep.28692 ↗
19. Acute renal failure associated with the new BRAF inhibitor vemurafenib10.1002/cncr.28709 ↗
20. Percutaneous absorption: a multiple pathway model10.1016/S0168-3659(96)01567-2 ↗
21. Discovery of transdermal penetration enhancers by high-throughput screening10.1038/nbt928 ↗
22. Transdermal protein delivery by a coadministered peptide identified via phage display10.1038/nbt1193 ↗
23. Microstereolithography and characterization of poly(propylene fumarate)-based drug-loaded microneedle arrays10.1088/1758-5090/7/4/045001 ↗
24. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery10.1016/j.biomaterials.2010.08.046 ↗
25. Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy10.1007/s11095-014-1436-x ↗
26. Storage stability and skin permeation of vitamin C liposomes improved by pectin coating10.1016/j.colsurfb.2014.02.036 ↗
27. Coadministration of oligomeric hyaluronic acid-modified liposomes with tumor-penetrating peptide-iRGD enhances the antitumor efficacy of doxorubicin against melanoma10.1021/acsami.6b13738 ↗
28. Sensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposome10.1016/j.biomaterials.2017.06.034 ↗
29. The next generation cell-penetrating peptide and carbon dot conjugated nano-liposome for transdermal delivery of curcumin10.1039/C5BM00433K ↗
30. Effective transcutaneous immunization using a combination of iontophoresis and nanoparticles10.1016/j.nano.2016.07.001 ↗
31. Ultrasound-mediated transdermal drug delivery: mechanisms, scope, and emerging trends10.1016/j.jconrel.2011.01.006 ↗
32. Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation10.1016/j.ijpharm.2011.10.031 ↗
33. Peptide-chaperone-directed transdermal protein delivery requires energy10.1021/mp500277g ↗
34. Cyclodextrins as permeation enhancers: some theoretical evaluations and in vitro testing10.1016/S0168-3659(98)00182-5 ↗
35. Topical delivery of hyaluronic acid into skin using SPACE-peptide carriers10.1016/j.jconrel.2013.10.007 ↗
36. Development of an efficient transdermal drug delivery system with TAT-conjugated cationic polymeric lipid vesicles10.1039/C3TB21353F ↗
37. Identification of a novel skin penetration enhancement peptide by phage display peptide library screening10.1021/mp200594z ↗
38. The transdermal inhibition of melanogenesis by a cell-membrane-permeable peptide delivery system based on poly-arginine10.1016/j.biomaterials.2014.01.052 ↗
39. Delivery of siRNA and other macromolecules into skin and cells using a peptide enhancer10.1073/pnas.1016152108 ↗
40. Development of a new topical system: drug-in-cyclodextrin-in-deformable liposome10.1016/j.ijpharm.2009.06.027 ↗
41. Quercetin deformable liposome: preparation and efficacy against ultraviolet B induced skin damages in vitro and in vivo10.1016/j.jphotobiol.2013.07.014 ↗
42. Enhanced corneal permeation of coumarin-6 using nanoliposomes containing dipotassium glycyrrhizinate: in vitro mechanism and in vivo permeation evaluation10.1039/C5RA13830B ↗
43. Identification of novel B-Raf(V600E) inhibitors employing FBDD strategy10.1016/j.bcp.2017.02.022 ↗
44. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes10.1016/S0022-3565(25)08751-8 ↗
45. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study10.2147/IJN.S156412 ↗
46. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination10.1016/j.jconrel.2016.01.020 ↗
47. Lipid-peg conjugates sterically stabilize and reduce the toxicity of phytantriol-based lyotropic liquid crystalline nanoparticles10.1021/acs.langmuir.5b02797 ↗
48. Cubosomes: remarkable drug delivery potential10.1016/j.drudis.2016.01.004 ↗
49. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate10.1016/j.jconrel.2017.12.023 ↗
50. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
51. Etodolac transdermal cubosomes for the treatment of rheumatoid arthritis: ex vivo permeation and in vivo pharmacokinetic studies10.1080/10717544.2017.1326539 ↗
52. Evaluation of meloxicam-loaded cationic transfersomes as transdermal drug delivery carriers10.1208/s12249-012-9904-2 ↗
53. Comparative study of novel ultradeformable liposomes: menthosomes, transfersomes and liposomes for enhancing skin permeation of meloxicam10.1248/bpb.b13-00576 ↗
54. Preparation and in vitro skin permeation of cubosomes containing hinokitiol10.1080/01932690903224862 ↗
55. Role of the Na+/K+-ATPase beta-subunit in peptide-mediated transdermal drug delivery10.1021/mp500789h ↗
56. Transdermal delivery of human epidermal growth factor facilitated by a peptide chaperon10.1016/j.ejmech.2012.12.054 ↗
57. Peptides as skin penetration enhancers: mechanisms of action10.1016/j.jconrel.2014.12.006 ↗
58. Effect of cationic cyclopeptides on transdermal and transmembrane delivery of insulin10.1021/mp300667p ↗
59. Nanoparticle elasticity directs tumor uptake